Results 131 to 140 of about 21,018 (198)

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

Lee J, Zhang LL, Wu W, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2(16):2039-2051. [PDF]

, 2018

openalex   +1 more source

Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

, 2023
Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien   +16 more
openalex   +1 more source

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. [PDF]

Sci Rep
Khan A, Ali SS, Zahid MA, Alshabrmi FM, Al-Zoubi RM, Shkoor M, Mohammmad A, Wei DQ, Agouni A.   +8 more
europepmc   +1 more source

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

, 2018
Anita Kumar, Santosha A. Vardhana, Alison J. Moskowitz, Pierluigi Porcu, Ahmet Doǧan, Jason A. Dubovsky, Matthew J. Matasar, Zhigang Zhang, Anas Younes, Steven M. Horwitz   +9 more
openalex   +1 more source

Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204. [PDF]

, 2019

openalex   +1 more source

Supplemental Figures 1-5 from Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

, 2023
Fabiola Cervantes-Gomez, Betty Lamothe, Jennifer A. Woyach, William G. Wierda, Michael J. Keating, Kumudha Balakrishnan, Varsha Gandhi   +6 more
openalex   +1 more source

Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population. [PDF]

Hemasphere
Ghia P, Ysebaert L, Janssens A, Stilgenbauer S, Fouad M, Schioppa CA, Hernández-Rivas JÁ, Tedeschi A.   +7 more
europepmc   +1 more source

Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort. [PDF]

Future Oncol
Munir T, Leão D, Messahel B, Srikanthan S, Xu P, Fouad M, Kavanagh C, Tapprich C, Miles O, Scheliga A, Ghia P.   +10 more
europepmc   +1 more source

PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management. [PDF]

Clin Exp Med
Kalaki NS, Karimi E, Allaei Rouzbahani K, Ahmadzadeh M, Akrami SM.   +4 more
europepmc   +1 more source